Quadria Capital Closes US$1 Billion Fund III to Back Healthcare Companies Across Asia

| Posted on |

Here’s a structured list based on the information provided:

Fund Details

  • Fund Name: Fund III
  • Total Commitments: $1.07 Billion
  • Original Target: $800 Million
  • Primary Commitments: $954 Million
  • Committed Co-investment Capital: $114 Million
  • Anticipated Additional Co-investment Capacity: $300 Million
  • Total Committed Capital upon Full Deployment: Approximately $1.3 Billion

Investors

  • Major Backers:
    • North American and European sovereign wealth funds
    • Asset managers
    • Strategic corporates
    • Institutional investors from the GCC (Saudi Arabia, UAE, Bahrain)
    • Banks, insurance companies, and family offices from India
    • Impact investors

Startup Investments

  1. Aragen Life Sciences (a global CRDMO serving over 400 pharma clients)
  2. NephroPlus (Asia’s largest dialysis chain)
  3. Maxivision (India’s leading eye care chain)

Founders

  • Dr. Amit Varma
  • Abrar Mir

Fundraising Series

  • This is referred to as Fund III.

Date of Announcement

  • Date: May 27, 2025

Additional Information

  • Quadria Capital was founded in 2012.
  • The firm manages over $4 Billion in assets across 27 investments in South and Southeast Asia (including India, Vietnam, Indonesia, Malaysia, and Singapore).

Source link

2025-05-27 09:00:29